DFV
Marboxidin 5 mg for cats and dogs 100 chewable tablets

Treatment of skin and soft tissue infections, urinary tract infections and respiratory tract infections in cats and dogs

Some countries require a prescription to be issued for the sale of this drug.

Marboxidin 5 mg is a brownish, oval, divisible and centre scored chewable tablet indicated for the treatment of infections:

  • In Dogs:
    • Skin and soft tissue infections (skinfold pyoderma, impetigo, folliculitis, furunculosis, cellulitis) caused by strains of microorganisms susceptible to marbofloxacin;
    • Urinary tract infections (UTI) associated or not with prostatitis or epididymitis caused by strains of microorganisms susceptible to marbofloxacin;
    • Respiratory tract infections caused by strains of microorganisms susceptible to marbofloxacin.
  • In cats
    • Marbofloxacin is indicated in the treatment of skin and soft tissue infections (wounds, abscesses, phlegmons) and upper respiratory tract infections caused by strains of microorganisms susceptible to marbofloxacin.

Each Marboxidin 5 mg tablet contains:

Active substance:

  • Marbofloxacin 5 mg

Excipients:

  • Glycerol distearate
  • Artificial beef flavour
  • Cellulose, microcrystalline
  • Starch, pregelatinized
  • Sodium starch glycolate (Type A)
  • Talc
  • Magnesium stearate

Marboxidin 5 mg:

  • Must not be used in dogs aged less than 12 months, or less than 18 months for exceptionally large breeds of dogs, such as Great Danes, Briard, Bernese, Bouvier and Mastiffs, with a longer growth period.
  • Is not recommended to use in cats aged less than 16 weeks.
  • Must not be used in animals with known hypersensitivity to marbofloxacin or other (fluoro)quinolones

Marboxidin 5 mg polosogy:

  • For oral administration.
  • The recommended dose rate is 2 mg/kg body weight/day (1 tablet for 2.5 kg BW per day) in single daily administration.
  • To ensure a correct dosage body weight should be determined as accurately as possible to avoid underdosing. Half of tablets can be administered.
  • Dogs:
    • In skin and soft tissue infections, treatment duration is at least 5 days. In superficial and severe pyoderma, treatment duration is at least 10 and 20 days, respectively. Depending on the course of the disease, it may be extended up to 40 days in urinary tract infections, treatment duration is at least 10 days. Depending on the course of the disease, it may be extended up to 28 days.
    • In respiratory infections, treatment duration is at least 7 days and depending on the course of the disease, it may be extended up to 21 days.
  • Cats:
    • For skin and soft tissue infections (wounds, abscesses, phlegmons) treatment duration is 3 to 5 days.
    • For upper respiratory infections treatment duration is 5 days.

Marboxidin 5 mg is a brownish, oval, divisible and centre scored chewable tablet indicated for the treatment of infections:

  • In Dogs:
    • Skin and soft tissue infections (skinfold pyoderma, impetigo, folliculitis, furunculosis, cellulitis) caused by strains of microorganisms susceptible to marbofloxacin;
    • Urinary tract infections (UTI) associated or not with prostatitis or epididymitis caused by strains of microorganisms susceptible to marbofloxacin;
    • Respiratory tract infections caused by strains of microorganisms susceptible to marbofloxacin.
  • In cats
    • Marbofloxacin is indicated in the treatment of skin and soft tissue infections (wounds, abscesses, phlegmons) and upper respiratory tract infections caused by strains of microorganisms susceptible to marbofloxacin.

Each Marboxidin 5 mg tablet contains:

Active substance:

  • Marbofloxacin 5 mg

Excipients:

  • Glycerol distearate
  • Artificial beef flavour
  • Cellulose, microcrystalline
  • Starch, pregelatinized
  • Sodium starch glycolate (Type A)
  • Talc
  • Magnesium stearate

Marboxidin 5 mg:

  • Must not be used in dogs aged less than 12 months, or less than 18 months for exceptionally large breeds of dogs, such as Great Danes, Briard, Bernese, Bouvier and Mastiffs, with a longer growth period.
  • Is not recommended to use in cats aged less than 16 weeks.
  • Must not be used in animals with known hypersensitivity to marbofloxacin or other (fluoro)quinolones

Marboxidin 5 mg polosogy:

  • For oral administration.
  • The recommended dose rate is 2 mg/kg body weight/day (1 tablet for 2.5 kg BW per day) in single daily administration.
  • To ensure a correct dosage body weight should be determined as accurately as possible to avoid underdosing. Half of tablets can be administered.
  • Dogs:
    • In skin and soft tissue infections, treatment duration is at least 5 days. In superficial and severe pyoderma, treatment duration is at least 10 and 20 days, respectively. Depending on the course of the disease, it may be extended up to 40 days in urinary tract infections, treatment duration is at least 10 days. Depending on the course of the disease, it may be extended up to 28 days.
    • In respiratory infections, treatment duration is at least 7 days and depending on the course of the disease, it may be extended up to 21 days.
  • Cats:
    • For skin and soft tissue infections (wounds, abscesses, phlegmons) treatment duration is 3 to 5 days.
    • For upper respiratory infections treatment duration is 5 days.
53.20
Order within 6h 37m 55s (before 12AM)
And receive your order
on Tuesday 24 October
AIR FREIGHT

Customers who buy this product, usually buy: